减毒活带状疱疹疫苗预防带状疱疹及相关并发症的长期有效性:韩国全国性模拟目标试验
本研究在韩国≥50岁全国性队列(n=2,519,582)中模拟目标试验,评估减毒活带状疱疹疫苗的长期有效性。重叠加权后910,602人中,接种与带状疱疹(aHR 0.48,95%CI 0.48-0.49)、带状疱疹后神经痛(0.47,0.46-0.48)、带状疱疹脑炎(0.40,0.25-0.63)及带状疱疹住院(0.33,0.31-0.35)风险降低相关;保护虽衰减但至8年仍显著。
要点
- 接种与带状疱疹风险降低相关(aHR 0.48,95%CI 0.48-0.49),RMST差异151.1天。
- 带状疱疹后神经痛aHR 0.47(0.46-0.48)、住院aHR 0.33(0.31-0.35),保护至8年仍显著。
- 男性、<60岁及每周饮酒少于1次者有效性更高。
核心结论
- 减毒活带状疱疹疫苗接种与韩国人群中带状疱疹及其并发症风险大幅降低相关;保护虽衰减但持续8年,支持该疫苗继续发挥作用,尤其在其他重组疫苗有限的情况下。
研究设计与样本
- 研究为基于韩国全国性人群队列的模拟目标试验,纳入≥50岁个体n=2,519,582,整合健康保险、国家健康筛查与疫苗接种数据。
- 暴露为2012年1月1日至2021年12月31日接种减毒活带状疱疹疫苗,随访至2024年1月31日。
- 采用Cox比例风险模型估计调整风险比(aHR)及95%CI,并在重叠加权队列中用限制性平均生存时间(RMST)评估至10年的有效性与持久性。
主要发现
- 重叠加权后910,602人(平均年龄61.48岁[SD 2.53],男性47.30%),接种与带状疱疹风险降低相关(aHR 0.48[95%CI 0.48-0.49];RMST差异151.1天)。
- 带状疱疹后神经痛aHR 0.47(0.46-0.48),RMST差异86.0天;带状疱疹脑炎aHR 0.40(0.25-0.63),RMST差异0.20天;带状疱疹住院aHR 0.33(0.31-0.35),RMST差异14.1天。
- 有效性随时间衰减,但至8年保护仍显著;带状疱疹后神经痛与住院也呈相似衰减模式。
- 男性、<60岁及每周饮酒少于1次者有效性更高。
临床怎么用
- 作者认为,尽管保护随时间衰减但持续8年,支持减毒活带状疱疹疫苗继续发挥作用,尤其在其他重组疫苗有限的情况下。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The live attenuated zoster vaccine is used to prevent herpes zoster in older individuals, but evidence on its durability remains limited, particularly across diverse populations and healthcare systems. We therefore assessed the long-term vaccine effectiveness of live attenuated zoster vaccine against herpes zoster and its complications in a nationally representative cohort of older individuals in South Korea. METHODS: We emulated target trial from a large-scale, population-based nationwide cohort of individuals aged ≥50 years in South Korea (n = 2,519,582), integrating health insurance data (Korea Health Insurance Review and Assessment Service), national health screening (Korean National Health Insurance Service), and live attenuated zoster vaccination data (Korea Disease Control and Prevention Agency). Exposure was defined as receiving the live attenuated zoster vaccine between January 1, 2012, and December 31, 2021, with a follow-up period through January 31, 2024. Outcomes included incident herpes zoster, postherpetic neuralgia, herpes zoster encephalitis, and hospital admission for herpes zoster. The effectiveness and durability were estimated using adjusted hazard ratios (aHRs) with 95 % confidence intervals (CIs) from Cox proportional hazard models and restricted mean survival time (RMST) up to 10 years in an overlap-weighted cohort. RESULTS: Among 910,602 individuals (mean age, 61.48 [SD, 2.53] years; 47.30 % males) after overlap weighting, vaccination was associated with significantly lower risks of herpes zoster (aHR, 0.48 [95 % CI 0.48-0.49]; RMST differences, 151.1 days), postherpetic neuralgia (0.47 [0.46-0.48]; 86.0 days), herpes zoster encephalitis (0.40 [0.25-0.63]; 0.20 days), and hospital admission for herpes zoster (0.33 [0.31-0.35]; 14.1 days). Although effectiveness declined, protection remained significant for up to 8 years. Similar waning patterns were observed for postherpetic neuralgia and hospital admissions. Greater effectiveness was observed in males, individuals aged <60 years, and those who consumed alcohol less than once per week. CONCLUSION: Live attenuated zoster vaccination was associated with substantially reduced risks of herpes zoster and its complications in South Korea. Despite waning, protection persisted for 8 years, supporting the continued role of live attenuated zoster vaccine, particularly where recombinant vaccines are limited.
引用
- Yeo D, Lee K, Jo Y, et al. Long-term effectiveness of live zoster vaccine against herpes zoster and related complications: a nationwide emulated target trial in South Korea. Vaccine. 2025. PMID: 41082816. doi:10.1016/j.vaccine.2025.127824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。